Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
NCT07459647

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

Led by MapLight Therapeutics · Updated on 2026-04-22

500

Participants Needed

5

Research Sites

200 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

CONDITIONS

Official Title

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able and willing to provide informed consent for all study procedures
  • Have a primary diagnosis of schizophrenia based on DSM-5 criteria confirmed by clinical interview
  • May benefit from long-term medication for schizophrenia as assessed by the investigator
  • Suitable for outpatient care and live in a stable living situation as assessed by the investigator
  • Have a reliable informant available to participate in assessments, such as site staff if in regular contact for over 1 year
Not Eligible

You will not qualify if you...

  • Have any DSM-5 disorder other than schizophrenia within the past 12 months that mainly causes current symptoms or problems
  • Are stopping effective and well-tolerated antipsychotic treatment just to join this study
  • Have used any prohibited therapy during screening unless stopped before baseline
  • Have a clinically significant or unstable medical condition at screening or baseline
  • Have abnormal physical exam, ECG, or safety lab results at screening or baseline
  • Have a high risk of suicidal behavior
  • Are allergic to ML-007C-MA or its ingredients
  • Have moderate to severe substance use disorder (except tobacco or caffeine) within past 12 months
  • Have a high risk of violent or destructive behavior based on history and investigator judgment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Clinical Site

Lemon Grove, California, United States, 91945

Actively Recruiting

2

Clinical Site

Miami Lakes, Florida, United States, 33016

Actively Recruiting

3

Clinical Site

Chicago, Illinois, United States, 60640

Actively Recruiting

4

Clinical Site

Staten Island, New York, United States, 10314

Actively Recruiting

5

Clinical Site

DeSoto, Texas, United States, 75115

Actively Recruiting

Loading map...

Research Team

C

Clinical Trials Contact Center

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia | DecenTrialz